• Nuclear Engineering and Technology
• /
• 제34권5호
• /
• pp.468-481
• /
• 2002

There are 4 CANDU6 type reactors operating at Wolsong site. For fuelling operation of certain fuel channels (with flow less than 21.5 kg/s) a FARE flow Assist Ram Extension) device is used. During the refuelling operation, two remote controlled F/Ms (Fuelling Machines) are attached to a designated fuel channel and carry out refuelling job. The upstream F/M inserts new fuel bundles into the fuel channel while the downstream F/M discharges spent fuel bundles. In order to assist fuelling operation of channels that has lower coolant How rate, the FARE device is used instead of F/M C-ram to push the fuel bundle string. The FARE device is essentially a How restricting element that produces enough drag force to push the fuel bundle string toward downstream F/M. Channels that require the use of FARE device for refuelling are located along the outside perimeter of reactor. This paper presents the FARE device design feature, steady state hydraulic and operational characteristics and behavior of the device when coupled with fuel bundle string during fuelling operation. The study showed that the steady state performance of FARE device meets the design objective that was confirmed by downstream F/M C-ram force to be positive.

• Journal of Korean Neurosurgical Society
• /
• 제63권2호
• /
• pp.137-152
• /
• 2020

In spite of the developing endovascular era, large (15-25 mm) and giant (>25 mm) wide-neck cerebral aneurysms remained technically challenging. Intracranial flow-diverting stents (FDS) were developed to address these challenges by targeting aneurysm hemodynamics to promote aneurysm occlusion. In 2011, the first FDS approved for use in the United States market. Shortly thereafter, the Pipeline of Uncoilable or Failed Aneurysms (PUFS) study was published demonstrating high efficacy and a similar complication profile to other intracranial stents. The initial FDA instructions for use (IFU) limited its use to patients 22 years old or older with wide-necked large or giant aneurysms of the internal carotid artery (ICA) from the petrous segment to superior hypophyseal artery/ophthalmic segment. Expanded IFU was tested in the Prospective Study on Embolization of Intracranial Aneurysms with PipelineTM Embolization Device (PREMIER) trial. With further post-approval clinical data, the United States FDA expanded the IFU to include patients with small or medium, wide-necked saccular or fusiform aneurysms from the petrous ICA to the ICA terminus. However, IFU is more restrictive in South Korea than in United States. Several systematic reviews and meta-analyses have sought to evaluate the overall efficacy of FDS for the treatment of cerebral aneurysms and consistently identify FDS as an effective technique for the treatment of aneurysms broadly with complication rates similar to other traditional techniques. A growing body of literature has demonstrated high efficacy of FDS for small aneurysms; distal artery aneurysms; non-saccular aneurysms posterior circulation aneurysms and complication rates similar to traditional techniques. In the short interval since the Pipeline Embolization Device was first introduced, FDS has been firmly entrenched as a powerful tool in the endovascular armamentarium. As new FDS are developed, established FDS are refined, and delivery systems are improved the uses for FDS will only expand further. Researchers continue to work to optimize the mechanical characteristics of the FDS themselves, aiming to optimize deploy ability and efficacy. With expanded use for small to medium aneurysms and posterior circulation aneurysms, FDS technology is firmly entrenched as a powerful tool to treat challenging aneurysms, both primarily and as an adjunct to coil embolization. With the aforementioned advances, the ease of FDS deployment will improve and complication rates will be further minimized. This will only further establish FDS deployment as a key strategy in the treatment of cerebral aneurysms.